[CCXI] ChemoCentryx, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 200.19 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 8.15 Change: 0.59 (7.8%)
Ext. hours: Change: 0 (0%)

chart CCXI

Refresh chart

Strongest Trends Summary For CCXI

CCXI is in the medium-term up 35% in 8 months and down -35% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe Crohn?s disease; CCX140 that is in Phase II clinical trial for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company?s drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated renal vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammato

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding44.29 M EPS-0.65 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-11.23
P/E To EPS Growth P/S P/BV2.01 Price/Cash Per Share2.67
Price/Free Cash Flow-5.77 ROA-44.16% ROE-47.68% ROI
Current Ratio9.82 Quick Ratio Long Term Debt/Equity Debt Ratio0.08
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities330 K Cash From Investing Activities18.71 M Cash From Operating Activities-9.68 M Gross Profit
Net Profit-12.01 M Operating Profit-12.11 M Total Assets107.34 M Total Current Assets76.05 M
Total Current Liabilities7.75 M Total Debt Total Liabilities7.93 M Total Revenue
Technical Data
High 52 week14.85 Low 52 week6.47 Last close7.75 Last change6.6%
RSI68.5 Average true range0.38 Beta1.23 Volume333.1 K
Simple moving average 20 days7.87% Simple moving average 50 days9.54% Simple moving average 200 days-22.45%
Performance Data
Performance Week6.02% Performance Month1.57% Performance Quart-4.44% Performance Half-40.06%
Performance Year-24.32% Performance Year-to-date-28.96% Volatility daily3.17% Volatility weekly7.1%
Volatility monthly14.55% Volatility yearly50.39% Relative Volume412.55% Average Volume409.42 K
New High New Low

News

2020-05-29 13:38:25 | Top Small Cap Stocks for June 2020

2020-05-18 08:30:10 | ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis FSGS

2020-05-16 10:49:56 | Analysts Have Just Cut Their ChemoCentryx, Inc. NASDAQ:CCXI Revenue Estimates By 11%

2020-05-14 06:53:09 | ChemoCentryx, Inc. NASDAQ:CCXI Just Reported And Analysts Have Been Cutting Their Estimates

2020-05-12 13:30:47 | ChemoCentryx Inc CCXI Q1 2020 Earnings Call Transcript

2020-05-12 09:30:46 | Edited Transcript of CCXI earnings conference call or presentation 11-May-20 9:00pm GMT

2020-05-11 19:55:11 | ChemoCentryx CCXI Reports Q1 Loss, Misses Revenue Estimates

2020-05-11 16:05:10 | ChemoCentryx Reports First Quarter 2020 Financial Results and Recent Highlights

2020-05-11 07:00:13 | Is There An Opportunity With ChemoCentryx, Inc.'s NASDAQ:CCXI 47% Undervaluation?

2020-05-04 08:30:10 | ChemoCentryx to Hold First Quarter 2020 Financial Results Conference Call on Monday, May 11, 2020

2020-04-27 12:31:04 | Analysts Estimate ChemoCentryx CCXI to Report a Decline in Earnings: What to Look Out for

2020-04-22 12:00:04 | Here's Why Momentum Investors Will Love ChemoCentryx CCXI

2020-04-07 12:00:04 | ChemoCentryx CCXI Upgraded to Buy: What Does It Mean for the Stock?

2020-03-31 16:52:45 | 5 Guru Stocks That Beat the Market

2020-03-16 09:47:01 | Why ChemoCentryx CCXI Stock Might be a Great Pick

2020-03-12 07:00:21 | ChemoCentryx, Inc. Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

2020-03-11 04:18:36 | Edited Transcript of CCXI earnings conference call or presentation 10-Mar-20 9:00pm GMT

2020-03-10 17:25:09 | ChemoCentryx CCXI Reports Q4 Loss, Tops Revenue Estimates

2020-03-10 16:05:10 | ChemoCentryx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

2020-03-10 15:00:00 | ChemoCentryx, Inc. to Host Earnings Call

2020-03-03 08:30:10 | ChemoCentryx to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, March 10, 2020

2020-03-02 12:30:05 | ChemoCentryx CCXI Expected to Beat Earnings Estimates: Should You Buy?

2020-02-19 08:30:10 | ChemoCentryx to Present at the 9th Annual SVB Leerink Global Healthcare Conference

2020-01-10 18:00:38 | Biotechs punch up talking points leading into big Union Square conference

2020-01-10 05:01:36 | Did The Underlying Business Drive ChemoCentryx's NASDAQ:CCXI Lovely 423% Share Price Gain?

2020-01-09 08:30:10 | ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital

2020-01-08 08:30:10 | ChemoCentryx to Present at the 38th Annual JP Morgan Healthcare Conference

2019-12-11 15:58:33 | Hedge Funds Dropped The Ball On ChemoCentryx Inc CCXI

2019-12-01 09:30:15 | The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

2019-11-29 11:24:04 | The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

2019-11-28 09:00:02 | ChemoCentryx CCXI Upgraded to Buy: What Does It Mean for the Stock?

2019-11-27 10:15:03 | Company News For Nov 27, 2019

2019-11-27 10:09:03 | Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More

2019-11-27 08:52:01 | ChemoCentryx Up on Encouraging Rare Disease Candidate Data

2019-11-27 07:26:05 | The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen

2019-11-26 14:03:22 | ChemoCentryx CCXI Stock Could Hit $40, Says Analyst

2019-11-26 13:26:00 | Drug maker ChemoCentryx shares rocket on blockbuster potential in rare autoimmune disease

2019-11-26 08:42:54 | Benzinga Pro's Top 5 Stocks To Watch For Tues., Nov. 26, 2019: BBY, CCXI, PANW, DLTR, DE

2019-11-26 08:30:10 | ChemoCentryx to Present at the 31st Annual Piper Jaffray Healthcare Conference

2019-11-26 08:14:36 | Dow Jones Futures: Palo Alto Networks Dives, Nutanix Soars; This Biotech Quadruples

2019-11-26 08:06:41 | The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

2019-11-26 07:00:29 | Market Morning: CBD Warning, Chemocentryx Win, Huge Tory Majority, Amazon Injuries

2019-11-26 01:00:00 | VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA Associated Vasculitis

2019-11-25 22:06:36 | Dow Jones Futures: Stock Market Fear Gauge Hits New Low; Palo Alto Networks Leads Six Big Movers

2019-11-25 18:11:00 | ChemoCentryx stock quadruples after 'transformational' vasculitis study

2019-11-25 16:05:10 | ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis

2019-11-25 08:54:01 | Are Options Traders Betting on a Big Move in ChemoCentryx CCXI Stock?

2019-11-20 17:32:55 | Plans filed for massive biotech campus in San Carlos

2019-11-11 08:33:38 | How Should Investors React To ChemoCentryx, Inc.'s NASDAQ:CCXI CEO Pay?

2019-11-05 08:30:00 | Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoCentryx Platform in Treatment of Complement 3 Glomerulopathy C3G and Focal Segmental Glomerulosclerosis FSGS